Moreover, since PKC is known to be activated in the kidney to pass the signal from angiotensin II and parathyroid hormone to regulate blood pressure and bone metabolism [33, 41], LAT2, whose function is clarified to be regulated by PKC, can also be related to those physiology and thus can serve as a potential drug target in the treatment of hypertensive disease and skeletal disease. The gene discussed is PRRT2; the disease is bone disorder.